Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Resch, B; Egger, B; Kurath-Koller, S; Urlesberger, B.
Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
Int J Infect Dis. 2017; 57(6):50-53 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Kurath-Koller Stefan
Resch Bernhard
Urlesberger Berndt
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
To obtain data on respiratory syncytial virus (RSV) associated hospitalization rates in preterm infants of 28 weeks gestational age and less in the era of palivizumab prophylaxis. Retrospective single-center cohort study including all preterm infants up to 28 weeks+6days gestational age and born between 2004 and 2012 at a tertiary care university hospital. Data on RSV related hospitalizations over the first two years of life covering at least two RSV seasons (November-April) were analyzed. Ninety-one of 287 (32%) infants were hospitalized due to respiratory illness, and a total of 17 infants (5.9%) tested RSV positive during the first 2 years of life. Fourteen infants (4.9%) were hospitalized during the first RSV season. RSV hospitalization rate in infants with BPD was 4.5% (2/44) compared to 4.9% (12/243) without BPD. Palivizumab prophylaxis was documented in 74.6% of the infants. Infants with RSV compared to other respiratory tract infection were of younger age (6.8 vs. 9.1 months; p=0.049), had longer hospital stays (median 11 vs. 5 days; p=0.043) and more severe respiratory illness (median LRI score 3 vs. 2; p=0.043). Despite palivizumab prophylaxis the burden of RSV disease and all cause respiratory illness was still remarkable in this vulnerable preterm population and mainly limited to the first season. Copyright © 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Antiviral Agents - therapeutic use
Cohort Studies -
Female -
Gestational Age -
Hospitalization -
Humans -
Infant, Extremely Premature -
Infant, Newborn -
Male -
Palivizumab - therapeutic use
Respiratory Syncytial Virus Infections - drug therapy
Respiratory Syncytial Virus Infections - epidemiology
Respiratory Syncytial Virus, Human -
Retrospective Studies -

Find related publications in this database (Keywords)
bronchopulmonary dysplasia
palivizumab
preterm infant
respiratory syncytial virus
respiratory tract infection
© Meduni Graz Impressum